These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 24854354)

  • 1. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
    Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
    Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.
    Pyo J; Cho SK; Kim D; Sung YK
    Korean J Intern Med; 2018 Nov; 33(6):1241-1251. PubMed ID: 29277097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
    Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
    Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists.
    Baričević D; Popović Grle S; Morović Vergles J; Čuković Čavka S; Jakopović M; Redžepi G; Boras Z; Baričević M; Samaržija M
    Acta Clin Croat; 2017 Jun; 56(2):203-209. PubMed ID: 29485786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.
    Cuomo G; D’Abrosca V; Iacono D; Pantano I
    Clin Rheumatol; 2017 Feb; 36(2):457-461. PubMed ID: 27817127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.
    Vassilopoulos D; Tsikrika S; Hatzara C; Podia V; Kandili A; Stamoulis N; Hadziyannis E
    Clin Vaccine Immunol; 2011 Dec; 18(12):2102-8. PubMed ID: 21994356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
    Ringrose JS; Sanche SE; Taylor-Gjevre RM
    Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome.
    Scrivo R; Sauzullo I; Mengoni F; Priori R; Coppola M; Iaiani G; DI Franco M; Vullo V; Mastroianni CM; Valesini G
    J Rheumatol; 2013 Feb; 40(2):157-65. PubMed ID: 23204217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
    Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
    Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.